Viridian Therapeutics, Inc.\DE (VRDN) Change in Accured Expenses (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Change in Accured Expenses history runs 14 years deep, the most recent figure standing at -$23.7 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 48.92% year-over-year to -$23.7 million; the TTM figure through Mar 2026 stood at $8.4 million (up 33.2% YoY), while the FY2025 annual figure was $16.2 million, down 24.04% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$23.7 million, down from $21.3 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $21.3 million in Q4 2025, with the low at -$23.7 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $3.9 million (2024), against an average of $1.5 million.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses surged 433.33% in 2023, then sank 1679.08% in 2025.
• Viridian Therapeutics, Inc.\DE's Change in Accured Expenses stood at $6.0 million in 2022, then slipped by 24.48% to $4.5 million in 2023, then surged by 138.05% to $10.8 million in 2024, then surged by 97.5% to $21.3 million in 2025, then sank by 211.12% to -$23.7 million in 2026.
• Business Quant data shows VRDN's Change in Accured Expenses at -$23.7 million in Q1 2026, $21.3 million in Q4 2025, and $4.6 million in Q3 2025.